X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs LUPIN LTD - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES LUPIN LTD DIVIS LABORATORIES/
LUPIN LTD
 
P/E (TTM) x 18.1 16.4 110.4% View Chart
P/BV x 3.9 3.8 102.6% View Chart
Dividend Yield % 1.6 0.8 195.9%  

Financials

 DIVIS LABORATORIES   LUPIN LTD
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-16
LUPIN LTD
Mar-16
DIVIS LABORATORIES/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs2,4842,127 116.8%   
Low Rs9181,294 70.9%   
Sales per share (Unadj.) Rs142.3304.1 46.8%  
Earnings per share (Unadj.) Rs41.950.4 83.1%  
Cash flow per share (Unadj.) Rs46.360.7 76.4%  
Dividends per share (Unadj.) Rs10.007.50 133.3%  
Dividend yield (eoy) %0.60.4 134.1%  
Book value per share (Unadj.) Rs161.5243.8 66.3%  
Shares outstanding (eoy) m265.47450.58 58.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x12.05.6 212.6%   
Avg P/E ratio x40.633.9 119.6%  
P/CF ratio (eoy) x36.728.2 130.2%  
Price / Book Value ratio x10.57.0 150.1%  
Dividend payout %23.914.9 160.4%   
Avg Mkt Cap Rs m451,525770,740 58.6%   
No. of employees `0003.716.4 22.7%   
Total wages/salary Rs m3,64921,077 17.3%   
Avg. sales/employee Rs Th10,184.48,379.6 121.5%   
Avg. wages/employee Rs Th984.11,289.0 76.3%   
Avg. net profit/employee Rs Th2,998.51,388.7 215.9%   
INCOME DATA
Net Sales Rs m37,764137,016 27.6%  
Other income Rs m8481,877 45.2%   
Total revenues Rs m38,612138,893 27.8%   
Gross profit Rs m14,13837,535 37.7%  
Depreciation Rs m1,1824,635 25.5%   
Interest Rs m23446 5.2%   
Profit before tax Rs m13,78134,330 40.1%   
Minority Interest Rs m0-88 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,66211,536 23.1%   
Profit after tax Rs m11,11922,707 49.0%  
Gross profit margin %37.427.4 136.7%  
Effective tax rate %19.333.6 57.5%   
Net profit margin %29.416.6 177.7%  
BALANCE SHEET DATA
Current assets Rs m30,94797,790 31.6%   
Current liabilities Rs m5,19553,872 9.6%   
Net working cap to sales %68.232.1 212.7%  
Current ratio x6.01.8 328.2%  
Inventory Days Days11785 137.9%  
Debtors Days Days85121 70.2%  
Net fixed assets Rs m17,02786,379 19.7%   
Share capital Rs m531901 58.9%   
"Free" reserves Rs m42,341105,735 40.0%   
Net worth Rs m42,877109,844 39.0%   
Long term debt Rs m553,739 0.0%   
Total assets Rs m49,684224,378 22.1%  
Interest coverage x595.077.9 763.4%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.80.6 124.5%   
Return on assets %22.410.3 217.3%  
Return on equity %25.920.7 125.4%  
Return on capital %32.221.2 151.8%  
Exports to sales %85.349.1 173.7%   
Imports to sales %22.97.4 307.9%   
Exports (fob) Rs m32,19867,244 47.9%   
Imports (cif) Rs m8,65410,199 84.9%   
Fx inflow Rs m32,27071,405 45.2%   
Fx outflow Rs m8,77517,807 49.3%   
Net fx Rs m23,49653,598 43.8%   
CASH FLOW
From Operations Rs m10,379-3,690 -281.3%  
From Investments Rs m-4,135-69,434 6.0%  
From Financial Activity Rs m-6,24158,126 -10.7%  
Net Cashflow Rs m3-14,998 -0.0%  

Share Holding

Indian Promoters % 52.0 46.6 111.6%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 11.8 11.3 104.4%  
FIIs % 19.0 31.9 59.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 10.1 170.3%  
Shareholders   31,796 98,259 32.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   BIOCON LTD  WOCKHARDT LTD.  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Lower; IT Stocks Witness Losses(11:30 am)

Share markets in India are presently trading marginally lower. Sectoral indices are trading on a mixed note with stocks in the IT sector and power sector witnessing maximum selling pressure.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 21, 2017 11:55 AM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - ALKEM LABORATORIES COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS